Sep 13, 2022 / 03:45PM GMT
Tejas Rajeev Savant - Morgan Stanley, Research Division - Equity Analyst
All right. My mic is on. I'm Tejas Savant. I'm the Life Science Tools and Diagnostics analyst at Morgan Stanley. It's my pleasure this afternoon to host Catalent. And from the company, we have Alessandro, Tom and Paul. So thank you all for doing this.
Before we get started, just need to wrap off the disclosure statement here. Please see the Morgan Stanley website at morganstanley.com/researchdisclosures. If you have any questions, do reach out to your sales rep.
Questions and Answers:
Tejas Rajeev Savant - Morgan Stanley, Research Division - Equity AnalystSo with that, Alessandro, maybe -- look, you've been at Catalent for a very long time, been in the hot seat for about 3 months now. Any early learnings you'd like to share? What has surprised you to the upside? And where do you think Catalent can do better as a company on a go-forward basis?
Alessandro Maselli - Catalent, Inc. - CEO & Director
Yes, sure. Number one, it's a
Trustpilot
